Press Release

PharmAla Data to be Published in ACS Chemical Neuroscience

Scientific Journal Article follows notable IP updates, including publication of key PCT Patent Application, presentation at International Society for Research into Psychedelics Conference

VANCOUVER, BC - February 20, 2024 - PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased that data from its computational Drug Discovery program, in conjunction with the University of Waterloo (laboratory of Dr. James Gauld) and made possible by funding from MITACS, will be published in the scientific journal ACS Chemical Neuroscience this week. The article “Uncovering Structure-Activity Relationships of Phenethylamines: Paving the Way for Innovative Mental Health Treatments” investigates the essential aspects of how the structure of phenethylamine molecules relates to their activity. It focuses on identifying key targets that are crucial for optimizing the safety and effectiveness of these compounds.

“PharmAla’s drug development program represents some of the world’s best work in the development of novel entactogenic molecules. This research opens new avenues for developing innovative treatments in mental health care,” said Dr. Harpreet Kaur, VP of Research at PharmAla Biotech. “We are pleased that our work with Dr. Gauld’s lab has continued to be both noted and considered highly by academic researchers and are proud to present some of the results of our drug discovery program in ACS Chemical Neuroscience.”

The publication follows the February 1 publication of the PCT patent application publication for PharmAla’s P1 molecule; PharmAla’s P1 patent application has been accepted for the Patent Prosecution Highway by the USPTO.

“Publication of our PCT filing for the P1 molecule should provide more context and information for potential drug development partners,” said Nick Kadysh, CEO, PharmAla Biotech. “As PharmAla continues to develop our drug development program – and begins work on our third generation of novel compounds – we look forward to additional collaborations with academic researchers worldwide.” PharmAla is also pleased that Dr. William Fantegrossi of the University of Arkansas for Medical Sciences represented PharmAla Biotech to present in-vivo data about PharmAla’s MDXX molecules at the International Society for Research into Psychedelics (ISRP) conference in New Orleans, Louisiana, on Saturday, February 17th 2024.

About PharmAla

PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. Our team of dedicated professionals includes regulatory experts, scientists, and biomanufacturing professionals. PharmAla has built what it believes to be North America’s first cGMP MDMA value chain, encompassing GMP manufacturing of Active Pharmaceutical Ingredient (API), and drug product formulation. PharmAla’s research and development unit has also begun preclinical research into two patented Novel Chemical Entities (NCEs) based on MDXX class molecules, with proof-of-concept research currently ongoing at the University of Arkansas Medical School.

Media Inquiries

Nicholas Kadysh, CEO